Clinical pharmacology

Impact factor: mean: 6.79, total: 81.46

Articles during the year 2015
  • Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1

    Mothe B, Climent N, Plana M, Rosas M, Jimenez JL, Muñoz-Fernandez MA, Puertas MC, Carrillo J, Gonzalez N, Leon A, Pich J, Arnaiz JA; Gatell JM, Clotet B, Blanco J, Alcamí J, Martinez-Picado J, Alvarez-Fernandez C, Sanchez-Palomino S, Guardo AC, Peña J, Benito J, Rallón N, Gomez C, Perdiguero B, Garcia-Arraiza J, Esteban M, López J, Brander C, Garcia F; RISVAC-03 Study Group
    J Antimicrob Chemother. 2015; 70: 1833-1842. IF: 5.313

  • Meropenem Population Pharmacokinetics in Critically Ill Patients with Septic Shock and Continuous Renal Replacement Therapy: Influence of Residual Diuresis on Dose Requirements

    Ulldemolins M, Soy D, Llaurado-Serra M, Vaquer S, Castro P, Rodríguez AH, Pontes C, Calvo G, Torres A, Martín-Loeches I
    Antimicrob Agents Chemother. 2015; 59(9): 5520-5528. IF: 4.476

  • Reversal of rivaroxaban-induced alterations on hemostasis by different coagulation factor concentrates – in vitro studies with steady and circulating human blood

    Escolar G, Arellano-Rodrigo E, Lopez-Vilchez I, Molina P, Sanchis J, Reverter JC, Carne X, Cid J, Villalta J, Tassies D, Galan AM, Diaz-Ricart M
    Circ J. 2015; 79(2): 331-338. IF: 3.94

  • Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleoside reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression

    Arribas JR, Girard PM, Landman R, Pich J, Mallolas J, Martínez-Rebollar M, Zamora FX, Estrada V, Crespo M, Podzamczer D, Portilla J, Dronda F, Iribarren JA, Domingo P, Pulido F, Montero M, Knobel H, Cabié A, Weiss L, Gatell JM; OLE/RIS-EST13 Study Group
    Lancet Infect Dis. 2015; 15(7): 785-792. IF: 22.433

  • Coagulation Factor Concentrates Fail to Restore Alterations in Fibrin Formation Caused by Rivaroxaban or Dabigatran in Studies With Flowing Blood From Treated Healthy Volunteers

    Arellano-Rodrigo E, Lopez-Vilchez I, Galan AM, Molina P, Reverter JC, Carné X, Villalta J, Tassies D, Lozano M, Díaz-Ricart M, Escolar G
    Transfus Med Rev. 2015; 29(4): 242-249. IF: 2.923

  • Evaluation of dose reduction versus standard dosing for maintenance of remission in patients with spondyloarthritis and clinical remission with anti-TNF (REDES-TNF): study protocol for a randomized controlled trial

    Pontes C, Gratacós J, Torres F, Avendaño C, Sanz J, Vallano A, Juanola X, de Miguel E, Sanmartí R, Calvo G
    Trials. 2015; 16(1): 370-0. IF: 1.731

  • [Adaptive authorization: a new way for the early access of new drugs?]

    Dal-Ré R, Carné X
    Med Clin (Barc). 2015; 144(6): 275-278. IF: 1.417